Adolor starts phase 1 study of novel Delta opioid agonist for pain management

By Lisa Kerner

Charlotte, N.C., Aug. 30 - Adolor Corp. began a phase 1 clinical trial to investigate the safety, tolerability and pharmacokinetics of a single dose of ADL5859, a novel, orally bioavailable Delta opioid receptor agonist, in healthy volunteers.

The Food and Drug Administration recently lifted the clinical hold on the company's Investigational New Drug application after reviewing Adolor's complete response.

"We are pleased to have been able to address the FDA's questions, refine the clinical protocol and commence our clinical program," chief scientific officer James Barrett said in a company news release.

"Discovered in-house, ADL5859 is Adolor's third product currently in clinical development and represents a new class of potential analgesics."

Adolor is an Exton, Pa.-based biopharmaceutical company specializing in pain management products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.